CDK4/CDK6 Inhibition as a Novel Strategy to Suppress the Growth and Survival of BCR-ABL1T315I+ Clones in TKI-resistant CML

EBioMedicine - Netherlands
doi 10.1016/j.ebiom.2019.11.004
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Inhibition of the BCR-Abl Tyrosine Kinase as a Therapeutic Strategy for CML

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

Coexistence of AML1/RUNX1 and BCR-ABL Point Mutations in an Imatinib-Resistant Form of CML

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Ectopic Expression of Cdk6 Circumvents Transforming Growth Factor-Β Mediated Growth Inhibition

Oncogene
Cancer ResearchGeneticsMolecular Biology
2001English

Adherence to BCR-ABL Inhibitors: Issues for CML Therapy

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

The Chimeric Ubiquitin Ligase SH2-U-box Inhibits the Growth of Imatinib-Sensitive and Resistant CML by Targeting the Native and T315i-Mutant BCR-ABL

Scientific Reports
Multidisciplinary
2016English

BCR-ABLT315I Transcript Disappearance in an Imatinib-Resistant CML Patient Treated With Homoharringtonine: A New Therapeutic Challenge?

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2007English

Downregulation of Γ-Catenin Inhibits CML Cell Growth and Potentiates the Response of CML Cells to Imatinib Through Β-Catenin Inhibition

International Journal of Molecular Medicine
MedicineGenetics
2012English

Selective JAK2/ABL Dual Inhibition Therapy Effectively Eliminates TKI-insensitive CML Stem/Progenitor Cells

Oncotarget
Oncology
2014English

A Novel BCR-Abl Splice Isoform Is Associated With the L248V Mutation in CML Patients With Acquired Resistance to Imatinib

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy